Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults - Trial NCT06367738
Access comprehensive clinical trial information for NCT06367738 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of California, Berkeley and is currently Not yet recruiting. The study focuses on Aging. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of California, Berkeley
Timeline & Enrollment
Phase 1
Apr 01, 2025
Dec 30, 2027
Primary Outcome
MRI measurements of brain structure
Summary
We will use cognitive exams, perceptual tasks, brain imaging, peripheral psychophysiology,
 and surveys to investigate the persisting effects of psilocybin on cognition, predictive
 coding, and affect in healthy older adults. We will measure changes in these measures by
 comparing baseline to one-week and one-month post-treatment. Participants will be randomly
 assigned to receive a dose of psilocybin in a range from microdose to moderate-to-high dose.
 Dose response will be assessed. Anatomical magnetic resonance imaging (MRI) and diffusion
 weighted imaging (DWI) will be used to assess changes in brain structure, while functional
 magnetic resonance imaging (fMRI) will be used to quantify changes in functional brain
 activity. We will assess whether changes in these brain measures underlie observed changes in
 cognition, predictive coding and affect.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06367738
Non-Device Trial